<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03027609</url>
  </required_header>
  <id_info>
    <org_study_id>AR-105-002</org_study_id>
    <nct_id>NCT03027609</nct_id>
  </id_info>
  <brief_title>Adjunctive Therapeutic Treatment With Human Monoclonal Antibody AR-105 (Aerucin®) in P. Aeruginosa Pneumonia</brief_title>
  <official_title>Placebo-controlled, Double-blind, Randomized Study of Aerucin® as Adjunct Therapy to Antibiotics in the Treatment of P. Aeruginosa Pneumonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aridis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aridis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, double-blind, randomized assessment of the efficacy, safety and pharmacokinetic
      of Aerucin® as adjunct treatment (in addition to standard of care antibiotics) for pneumonia
      caused by P. aeruginosa.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, placebo-controlled study of the human monoclonal antibody
      (mAb) AR-105 for the adjunctive therapeutic treatment of P. aeruginosa pneumonia in
      mechanically ventilated subjects. Subjects who are randomized will be treated with either
      standard of care (SOC) antibiotics plus placebo or SOC antibiotics plus AR-105. The study is
      being conducted at approximately 90 clinical sites across 13 countries. Subjects who meet all
      of the inclusion criteria and none of the exclusion criteria are screened by the
      microbiological culture test and/or rapid diagnostic test of an endotracheal aspirate to
      confirm the presence of an active P. aeruginosa infection. Following eligibility
      confirmation, the subject will be randomized in a 1:1 ratio to one of two treatment groups.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 29, 2017</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure: treatment success, treatment failure</measure>
    <time_frame>21 days following dosing</time_frame>
    <description>Clinical cure as adjudicated by committee</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality, all-cause</measure>
    <time_frame>28 days following dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiological outcome: eradicated, not eradicated</measure>
    <time_frame>28 days following dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Economics assessments: time ventilated, time in ICU, time in the hospital</measure>
    <time_frame>28 days following dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - adverse events</measure>
    <time_frame>28 days following dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - immunogenicity</measure>
    <time_frame>28 days following dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic: AR-105 blood level</measure>
    <time_frame>28 days following dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">108</enrollment>
  <condition>Pseudomonas Aeruginosa Pneumonia</condition>
  <arm_group>
    <arm_group_label>AR-105</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One intravenous infusion of AR-105 20mg/'kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AR-105</intervention_name>
    <description>monoclonal antibody</description>
    <arm_group_label>AR-105</arm_group_label>
    <other_name>Aerubumab</other_name>
    <other_name>Aerucin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>matching placebo</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  ≥18 years of age, ≥ 20 years of age (Taiwan only)

          -  pneumonia due to P. aeruginosa

          -  ventilated

          -  intubated

          -  APACHE II score between 10 and 35

        Exclusion Criteria (main criteria):

          -  being moribund

          -  effective antibiotic therapy ≥48 hours

          -  immunocompromised

          -  underlying pulmonary disease that may preclude the assessment of a therapeutic
             response
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bruno François, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital Dupuytren</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wolfgang Dummer, MD, PhD</last_name>
    <phone>408-385-1742</phone>
    <email>dummerw@aridispharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yu Ping Yen, PhD</last_name>
    <phone>408-385-1742</phone>
    <email>yeny@aridispharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2017</study_first_submitted>
  <study_first_submitted_qc>January 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2017</study_first_posted>
  <last_update_submitted>April 19, 2018</last_update_submitted>
  <last_update_submitted_qc>April 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pseudomonas aeruginosa</keyword>
  <keyword>pneumonia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Pseudomonas Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

